Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075673 · ClinicalTrials.gov registry record · Phase 1
Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00075673 is a Phase 1 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 6 participants.
The verdict
NCT00075673, a Phase 1 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining vinorelbine with celecoxib may kill more tumor cells. PURPOSE: Phase I trial to determine the effectiveness of combining vinorelbine with celecoxib in treating women who have relapsed or metastatic breast cancer.
Interventions
- DRUG celecoxib
- DRUG vinorelbine ditartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2003-11 |
| Est. Completion | 2005-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00075673
The ClinicalTrials.gov registry entry for NCT00075673 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which celecoxib is the first listed.
NCT00075673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00075673 about?
NCT00075673 is a clinical study titled "Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer". RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining vinorelbine with celecoxib may kill more t...
What is the current status of trial NCT00075673?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2003-11. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00075673?
The interventions under investigation include: celecoxib (DRUG), vinorelbine ditartrate (DRUG).
Who is sponsoring clinical trial NCT00075673?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.